BioMimetic Therapeutics, Inc. (NASDAQ:BMTI)
| CAPS Rating |
|
|---|---|
| Open | $2.20 |
| Previous Close | $2.23 |
| Daily Range | $2.11 - $2.22 |
| 52-Week Range | $1.87 - $14.49 |
| Market Cap | $59.72M |
| P/E Ratio | 0.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 290,405 |
| Average Daily Volume | 0 |
BMTI
VS S&P 500 (SPY)
How do you think BMTI will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
BMTI Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
BMTI News and Commentary
- 5 of Last Week's Biggest Losers – The Motley Fool
- US Stock Futures: HOT STOCKS TO WATCH – SmartMoney
- US Stock Futures: HOT STOCKS TO WATCH – SmartMoney
- Up 20%, but Uncertainty Still Looms – The Motley Fool
- 5 of Last Week's Biggest Losers – The Motley Fool
- See Drug, Approve Drug – The Motley Fool
- 5 of Last Week's Biggest Losers – The Motley Fool
- FDA Advisory Panel Positive! Shares Punished. – The Motley Fool
- Tough Talk From the FDA Batters BioMimetic – SeekingAlpha
- Tuesday Options Recap – SeekingAlpha
- 9 Healthcare Companies Expecting May Catalysts – SeekingAlpha
- Thursday Options Brief: SFD, SD, CBS & BMTI – SeekingAlpha
- BioMimetic: What the Bulls Are Seeing – SeekingAlpha
- The Promise of Stem Cells: Which Insider Executives Are Buying Into Their Own Technology? – The Motley Fool
- The Top 20 Most Undervalued Healthcare Stocks By Target Price – NASDAQ
- Conservative Growth/Balanced Ideas for 2011 – SeekingAlpha
- Biotech: Update on Deals, Mergers, Funding – SeekingAlpha
- UPDATE 1-BioMimetic's bone product trial disappoints, shrs tank – Reuters
- Stocks the Rich Executives Are Buying – The Motley Fool
- Treading on a Johnson & Johnson Product – The Motley Fool
RSS Headlines
Fool UK
